AC	Anticoagulation
AE	Adverse event
AF	Atrial fibrillation
BOR	Best overall response
BRAF/MEKi	BRAF/MEK inhibitors
CI	Confidence interval
cICI	Combined immune checkpoint inhibitor therapy
CR	Complete response
CTL	Cytotoxic T-lymphocytes
DC	Dendritic cells
DCR	Disease control rate
DOAC	Direct oral anticoagulant(s)
DVT	Deep vein thrombosis
FXa-i	Factor Xa-inhibitors
HR	Hazard ratio
ICI	Immune checkpoint inhibitors
IFN	Interferon
IPI	Ipilimumab
LMWH	Low-molecular-weight heparins
MBM	Melanoma brain metastases
Mφ	Macrophage(s)
MR	Mixed response
NED	No evidence of disease
Nivo	Nivolumab
ORR	Objective response rate
OS	Overall survival
PAR	Protease activated receptors
PD	Progressive disease
PD-1	Programmed-cell-death protein 1
PD-L1	Programmed-cell-death ligand 1
PE	Pulmonary embolism
Pembro	Pembrolizumab
PFS	Progression-free survival
PR	Partial response
RECIST	Response Evaluation Criteria in Solid Tumors
SD	Stable disease
TEE	Thromboembolic events
TF	Tissue factor
TME	Tumor microenvironment
VKA	Vitamin K antagonists
VTE	Venous thromboembolic events